Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 juin 2016 07h00 HE | Source: Akari Therapeutics, Plc

Akari Therapeutics to Present at the JMP 2016 Life Sciences Conference

NEW YORK and LONDON, June 15, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Dr. Gur Roshwalb, Chief...
26 mai 2016 07h00 HE | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference

NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
23 mai 2016 07h10 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome

NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
19 mai 2016 07h30 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated

NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin...
12 mai 2016 16h05 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome

NEW YORK and LONDON, May 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
14 avr. 2016 07h30 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a...
31 mars 2016 16h03 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...
01 mars 2016 07h15 HE | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

NEW YORK and LONDON, March 01, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that Gur Roshwalb, M.D.,...
17 févr. 2016 07h15 HE | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day

NEW YORK and LONDON, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that members of its...
29 janv. 2016 07h05 HE | Source: Akari Therapeutics Plc

Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

NEW YORK and LONDON, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the approval by the UK...

Page précédente